FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $49,461,000 | +5.3% | 569,889 | 0.0% | 79.24% | +30.1% |
| Q1 2021 | $46,987,000 | -9.3% | 569,889 | 0.0% | 60.92% | -9.9% |
| Q4 2020 | $51,820,000 | +51.7% | 569,889 | -33.3% | 67.63% | +20.0% |
| Q3 2020 | $34,168,000 | -12.6% | 854,836 | -25.0% | 56.34% | +85.1% |
| Q2 2020 | $39,106,000 | +54.5% | 1,139,783 | 0.0% | 30.44% | +32.8% |
| Q1 2020 | $25,315,000 | +13.5% | 1,139,783 | 0.0% | 22.91% | +41.2% |
| Q4 2019 | $22,306,000 | +26.0% | 1,139,783 | 0.0% | 16.22% | +61.3% |
| Q3 2019 | $17,701,000 | -40.8% | 1,139,783 | -22.6% | 10.06% | -57.2% |
| Q2 2019 | $29,906,000 | +15.5% | 1,473,186 | 0.0% | 23.49% | +7.2% |
| Q1 2019 | $25,884,000 | +10.7% | 1,473,186 | -19.2% | 21.90% | -12.3% |
| Q4 2018 | $23,391,000 | -41.9% | 1,823,186 | -26.3% | 24.97% | +23.8% |
| Q3 2018 | $40,288,000 | +43.6% | 2,473,186 | 0.0% | 20.17% | +32.0% |
| Q2 2018 | $28,046,000 | +16.2% | 2,473,186 | 0.0% | 15.28% | +11.1% |
| Q1 2018 | $24,138,000 | +59.7% | 2,473,186 | 0.0% | 13.76% | +3.3% |
| Q4 2017 | $15,111,000 | +54.3% | 2,473,186 | 0.0% | 13.32% | +58.2% |
| Q3 2017 | $9,794,000 | +22.2% | 2,473,186 | 0.0% | 8.42% | +1.6% |
| Q2 2017 | $8,013,000 | -28.8% | 2,473,186 | 0.0% | 8.29% | -31.2% |
| Q1 2017 | $11,253,000 | +81.3% | 2,473,186 | 0.0% | 12.05% | +63.5% |
| Q4 2016 | $6,208,000 | -19.5% | 2,473,186 | 0.0% | 7.37% | -9.5% |
| Q3 2016 | $7,716,000 | +83.5% | 2,473,186 | 0.0% | 8.15% | +80.5% |
| Q2 2016 | $4,204,000 | -5.6% | 2,473,186 | 0.0% | 4.51% | +6.1% |
| Q1 2016 | $4,452,000 | -46.6% | 2,473,186 | 0.0% | 4.25% | -35.0% |
| Q4 2015 | $8,335,000 | -36.8% | 2,473,186 | 0.0% | 6.55% | -27.1% |
| Q3 2015 | $13,182,000 | -17.6% | 2,473,186 | 0.0% | 8.98% | +25.8% |
| Q2 2015 | $16,002,000 | +32.3% | 2,473,186 | 0.0% | 7.14% | +32.1% |
| Q1 2015 | $12,094,000 | -2.8% | 2,473,186 | 0.0% | 5.40% | -45.1% |
| Q4 2014 | $12,440,000 | -1.4% | 2,473,186 | 0.0% | 9.84% | +1.1% |
| Q3 2014 | $12,613,000 | -19.2% | 2,473,186 | 0.0% | 9.73% | -23.5% |
| Q2 2014 | $15,606,000 | -35.2% | 2,473,186 | 0.0% | 12.72% | -36.4% |
| Q1 2014 | $24,089,000 | – | 2,473,186 | – | 20.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |